Application of FuHsi microprotein in enhancement of protein expression and diagnosis and treatment of tumors
Through the application of FuHsi microprotein and its related molecules, the gap in microprotein in the existing technology in tumor diagnosis and treatment has been solved, the promotion of protein production and the regulation of tumor cell proliferation has been achieved, and new targets have been provided for tumor treatment. points and diagnostic markers improve the accuracy of diagnosis and treatment.
Patent Information
- Application Number
- CN202411155847.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-27
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-29
AI Technical Summary
There is a lack of effective utilization of microproteins in existing anti-tumor and tumor diagnostic technologies, especially in applications in organisms.
It proposes the application of FuHsi microprotein and its related promoters, inhibitors and detection reagents to improve the yield of proteins or antibodies, tumor detection and adverse prognosis evaluation, and to prepare anti-tumor drugs through specific amino acid sequences and lncRNA Knockdown or knockout technique.
Through a variety of technical means, such as high-throughput RNA sequencing, ribosome isolation and immunofluorescence detection, FuHsi microprotein regulates rDNA transcription and nucleolar formation, promotes protein production, and provides new targets and diagnostic markers for tumor treatment. , improves the proliferation and diagnostic accuracy of tumor cells.
Smart Images

Figure CN119044494A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to the application of FuHsi microprotein in enhancing protein expression, diagnosis and treatment of tumors. Background Art
[0002] At present, the research on anti-tumor and tumor diagnosis technology is mostly focused on molecular drugs, gene drugs, peptides, etc. However, the exploration of microproteins in organisms and their application in tumor treatment and diagnosis is still relatively blank. Summary of the invention
[0003] In view of the deficiencies of the prior art, the present invention proposes an application of FuHsi microprotein in enhancing protein expression, diagnosis and treatment of tumors.
[0004] The purpose of the present invention can be achieved through the following technical solutions:
[0005] The first aspect of the present invention relates to an application of FuHsi microprotein, including any one of the following applications:
[0006] Application of FuHsi microprotein or its promoter in increasing protein or antibody production of cells;
[0007] Application of FuHsi microprotein detection reagent in the preparation of a kit for tumor detection or poor prognosis assessment;
[0008] and, the use of inhibitors of FuHsi microproteins in the preparation of anti-tumor drugs;
[0009] Among them, the amino acid sequence of the FuHsi microprotein is: SEQ ID NO.1.
[0010] Optionally, the detection reagent of the FuHsi microprotein includes Anti-FuHsi antibody.
[0011] Optionally, the inhibitor is shRNAs capable of knocking down the lncRNA corresponding to FuHsi, including:
[0012] sh-1, sequence: SEQ ID NO.3;
[0013] sh-2, sequence: SEQ ID NO.4.
[0014] Optionally, the promoter includes lncRNADLGAP1-AS2, the sequence of which is: SEQ ID NO.2 and the coding sequence of FuHsi microprotein, the sequence of which is: SEQ ID NO.6.
[0015] In addition, it should be noted that inhibitors also include other reagents that can produce or express FuHsi microproteins, such as reagents that knock out the genetic information related to the microprotein FuHsi, or reagents that interfere with the expression or production of the microprotein FuHsi.
[0016] Optionally, the tumor is lung adenocarcinoma.
[0017] The third aspect of the present invention relates to an anti-tumor drug, including an inhibitor of FuHsi microprotein, wherein the amino acid sequence of the FuHsi microprotein is: SEQ ID NO.1.
[0018] Optionally, a carrier for delivering the inhibitor is also included.
[0019] The fourth aspect of the present invention relates to a kit, comprising a reagent for detecting the content or expression level of FuHsi microprotein, wherein the amino acid sequence of the FuHsi microprotein is: SEQ ID NO.1.
[0020] Beneficial effects of the present invention:
[0021] Through RNA high-throughput sequencing, ribosome separation, RNA nucleic acid electrophoresis, qRT-PCR, dual fluorescence reporter enzyme experiments, protein immunoblotting, immunofluorescence, electron microscopy detection technology and other technical means, it was revealed that the microprotein FuHsi regulates rDNA transcription and nucleolus formation and promotes protein production. In some technologies for preparing proteins or antibodies through cells, the production of proteins or antibodies can be increased by using microprotein FuHsi or reagents that promote microprotein FuHsi.
[0022] Finally, immunohistochemistry, RNA electrophoresis and cell proliferation experiments revealed that FuHsi can promote the growth of tumor cells in vivo and in vitro, and high expression of FuHsi is associated with poor prognosis of LUAD, which provides new therapeutic targets and diagnostic markers for tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The present invention will be further described below in conjunction with the accompanying drawings.
[0024] Figure 1 This is a schematic diagram of the experimental results related to verifying that FuHsi is a microprotein located in the nucleolus in Example 1 of the present application; wherein, Figure 1 A in the figure is the protein expression of FuHsi detected by western blotting experiment; Figure 1 B in the figure is the detection of endogenous FuHsi by Co-IP and silver staining; Figure 1 C in the figure is the secondary mass spectrometry peak of endogenous FuHsi detected by mass spectrometry technology; Figure 1D and E in the figure are the relative expression levels of DLGAP1 and DLGAP1-AS2 in NCI-H1299 cells transfected with the corresponding vectors detected by qRT-PCR (D) or Western blotting (E); Figure 1 F in the figure is the knockdown efficiency of FuHsi and the specificity of FuHsi antibody detected by immunofluorescence experiment; Figure 1 G in the figure indicates the cellular localization of FuHsi and the lncRNA FuHsi encoding it detected by FISH and immunofluorescence experiments.
[0025] Figure 2 In Example 1 of the present application, wherein, Figure 2 A in the figure is the RNAseq result of KEGG analysis of FuHsi knockdown cells; Figure 2 B in the figure is the RNAseq result of GO analysis of FuHsi knockdown cells; Figure 2 C in the figure is the GSEA result of the corresponding pathway in Figures A and B.
[0026] Figure 3 This is a schematic diagram of the effect of FuHsi KD on rDNA transcription in this application, wherein: Figure 3 A in the figure shows the effect of knocking down FuHsi on ribosomal 40S and 60S subunits, as well as 80S ribosomes; Figure 3 B in the figure shows the effect of knocking down FuHsi on ribosomal 18S and 28S rRNA; Figure 3 C in the figure shows the effect of knocking down FuHsi on the expression of total pre-rRNA; Figure 3 D in the figure shows the effect of knocking down FuHsi on the expression and localization of total pre-rRNA; Figure 3 E in the figure shows the effect of knocking down FuHsi on the expression of nascent pre-rRNA; Figure 3 F in the figure represents the effect of knocking down FuHsi on rDNA promoter transcription.
[0027] Figure 4 This is a schematic diagram of the effect of FuHsi KO on rDNA transcription in this application, wherein: Figure 4 AC in the figure are the effects of FuHsi-KO on lncRNA and microprotein FuHsi in NCI-H1299 cells detected by qRT-PCR (A), immunofluorescence (B), and immunoblotting (C); Figure 4 D in the figure represents the effect of FuHsi-KO on ribosomal 18S and 28S rRNA; Figure 4 E in the figure represents the effect of FuHsi-KO on total pre-rRNA expression; Figure 4 F in the figure represents the effect of FuHsi-KO on the expression of nascent pre-rRNA; Figure 4The G in the figure represents the effect of FuHsi-KO on rDNA promoter transcription.
[0028] Figure 5 This is a schematic diagram of the effect of FuHsi OE on rDNA transcription in this application, wherein: Figure 5 A in the figure indicates RNA expression detected by qRT-PCR; Figure 5 B in the figure shows protein expression by immunoblotting; Figure 5 C in the figure shows the effect of overexpression of lncRNA and microprotein FuHsi on ribosomal 18S and 28S rRNA; Figure 5 D in the figure shows the effect of overexpression of lncRNA and microprotein FuHsi on total pre-rRNA expression; Figure 5 E in the figure represents the effect of overexpression of lncRNA and microprotein FuHsi on rDNA promoter transcription.
[0029] Figure 6 This is a schematic diagram of the experimental results of the promoting effect of FuHsi on total protein in Example 2 of the present application.
[0030] in Figure 6 The left side shows the inhibitory effect of knocking down FuHsi on total protein production; the right side shows the promoting effect of overexpressing microprotein FuHsi on total protein production.
[0031] Figure 7 Schematic diagram of the effect of FuHsi on the nucleolus in Example 2 of the present application; wherein, Figure 7 AD in the figure are immunofluorescence experiments to detect the effect of knocking down FuHsi on the nucleolar localization of FuHsi, UBF, RPA194, FBL and NPM1; Figure 7 FH in the figure is the effect of FuHsi-KO on the nucleolar localization of FuHsi, UBF, RPA194 and FBL detected by immunofluorescence experiment; Figure 7 I in the figure represents the effect of knocking down FuHsi on the nucleolus detected by electron microscopy.
[0032] Figure 8 This is a schematic diagram of the predictive effect of FuHsi expression level on lung adenocarcinoma in Example 3 of the present application; wherein, Figure 8 A in the figure is the analysis of the survival of LUAD patients using the FuHsi expression score of LUAD patients in TCGA; Figure 8 B and C in the figure are representative images of immunohistochemical staining of FuHsi expression in LUAD tumors and adjacent tissues (B) and quantification of expression scores (C).
[0033] Fig. 9 The effect of the expression change of FuHsi in Example 4 of the present application on the proliferation of tumor cells in vitro; wherein, Fig. 9A in the figure is the effect of knocking down FuHsi on the cell proliferation ability of NCI-H1299 cells detected by CTG method; Fig. 9 B and C in the figure are the effects of knocking down FuHsi on the colony formation of NCI-H1299 cells, (B) is a schematic diagram, and (C) is the quantitative data; D in 9 is the CTG method for detecting the cell proliferation ability of NCI-H226 cells transfected with the corresponding plasmids.
[0034] Fig.10 The effect of the expression change of FuHsi in Example 5 of the present application on the proliferation of tumor cells in vivo; wherein, Fig.10 A in the figure shows the effect of knocking down FuHsi on the growth of NCI-H1299 cells in subcutaneous transplanted tumors in nude mice; Fig.10 B and C in the figure show the effect of knocking down FuHsi on the size (B) and mass (C) of subcutaneous transplanted tumors of NCI-H1299 cells in nude mice. (n=6); Fig.10 D and E in the figure are representative images of FuHsi IHC staining of exfoliated subcutaneous tumors (D) and quantification of expression scores (E); Fig.10 F in the figure is the effect of gel electrophoresis on the total RNA samples of the corresponding tumor tissue cells to analyze the effects on 28S and 18S rRNA; DETAILED DESCRIPTION
[0035] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0036] Example 1 Verification that FuHsi is an endogenous microprotein in cells
[0037] like Figure 1As shown, in order to confirm that the microprotein FuHsi is an endogenous natural protein, this example prepared a rabbit polyclonal antibody Anti-FuHsi that can recognize its specific peptide segment. In order to detect whether the Anti-FuHsi antibody can recognize the endogenous microprotein FuHsi in the cell, this example designed and constructed two shRNAs that specifically knock down lncRNA DLGAP1-AS2, including: sh-1, sequence: SEQ ID NO.3; sh-2, sequence: SEQ ID NO.4. After knocking down the expression of DLGAP1-AS2 in NCI-H1299 cells, qRT-PCR and protein immunoblotting experiments were used for detection and verification, confirming that the Anti-FuHsi antibody can detect the endogenous microprotein FuHsi; shRNAs knockdown (hereinafter referred to as FuHsi KD) will significantly inhibit FuHsi and DLGAP1-AS2, but will not affect the expression of DLGAP1.
[0038] Using this polyclonal antibody, this example was tested by protein immunoprecipitation-polyacrylamide gel electrophoresis-silver staining experiment, and a protein band of the expected size was found. LC-MS / MS detection was performed on it, and 3 specific peptides that completely matched the microprotein FuHsi were obtained.
[0039] Using this polyclonal antibody, this example found through immunofluorescence and fluorescence in situ hybridization experiments that FuHsi was localized in the nucleolus, while DLGAP1-AS2 was localized in the nucleoplasm.
[0040] Example 2 Microprotein FuHsi regulates rDNA transcription and promotes protein production
[0041] like Figure 2 As shown, in order to confirm which function of the nucleolus FuHsi is involved in regulating, RNA high-throughput sequencing was performed on FuHsi KD cells and control cells derived from NCI-H299 cells in the examples of this application, and GSEA analysis was performed on the RNA-seq data. KEGG analysis showed that it mainly affected the ribosome and RNA polymerase pathways; GO analysis showed that the biogenesis of the large and small ribosome subunits and the ribosome assembly pathway in the FuHsiKD group were significantly inhibited. This indicates that the microprotein FuHsi may be involved in regulating the biogenesis of the ribosome, the main function of the nucleolus.
[0042] like Figures 3 to 5As shown, in order to confirm that FuHsi is involved in the step of ribosome formation, the effects of FuHsiKD, FuHsi knockout (hereinafter referred to as FuHsi KO) and FuHsi overexpression (hereinafter referred to as FuHsi OE) on NCI-H1299 and 293T cells were detected in the examples of the present application by ribosome separation, RNA nucleic acid electrophoresis, qRT-PCR, and dual fluorescence reporter enzyme experiments. It was found that both FuHsi KD and FuHsi KO significantly inhibited the expression or production of 40S and 60S ribosomal subunits and 80S ribosomes, 18S and 28S rRNA, total 47S pre-rRNA and nascent pre-rRNA, and rDNA promoters. FuHsi OE and DLGAP1-AS2 OE both significantly promoted the expression or production of 18S and 28S rRNA, total 47S pre-rRNA, and rDNA promoters.
[0043] like Figure 6 As shown, FuHsi KD can inhibit the production of total protein in 293T or NCI-H1299 cells; FuHsiOE can promote the production of total protein in 293T or NCI-H1299 cells.
[0044] like Figure 7 As shown, this example also found through immunofluorescence experiments that FuHsi KD and FuHsi KO will cause markers of various nucleolar components including UBF, RPA194, FBL and NPM, and even rDNA to disappear from the nucleolar region. Electron microscopy also found that the nucleolar structure disappeared in the cells of the FuHsi KD group. These results indicate that the nucleolar localization of each component protein in the nucleolus depends on FuHsi, and FuHsi maintains the existence of the nucleolus; at the same time, this also suggests that FuHsi may be an essential structural component of the nucleolus.
[0045] Example 3: Association between FuHsi and LUAD
[0046] like Figure 8 As shown, in this example, information from the TCGA database was analyzed, and it was found that high expression of DLGAP1-AS2 (the coding gene of the microprotein FuHsi) was associated with low survival rate in patients with lung adenocarcinoma (LUAD). In order to further confirm the clinical significance of this finding, this example performed immunohistochemical staining on a tissue microarray containing 85 pairs of LUAD tissues and their corresponding paracancerous tissues. The experimental results showed that FuHsi expression was significantly upregulated in the nuclei of LUAD tissues.
[0047] Example 4 Effect of FuHsi expression changes on tumor cell proliferation in vitro
[0048] like Fig. 9 As shown, in this example, the effect of the expression change of FuHsi on the in vitro cell phenotype was detected. The results showed that FuHsi KD significantly inhibited the proliferation and colony formation ability of NCI-H1299 cells; FuHsi OE and DLGAP1-AS2OE both significantly promoted the proliferation ability of NCI-H226 cells, while MUT OE had little effect on cell proliferation. These results show that FuHsi can promote the proliferation of tumor cells in vitro, and the promotion of DLGAP1-AS2 on the proliferation of tumor cells in vitro is due to the microprotein FuHsi it encodes, rather than its RNA itself.
[0049] Effects of 5FuHsi expression changes on tumor cell proliferation in vivo (nude mouse subcutaneous tumor model)
[0050] like Fig.10 As shown, this example also uses a nude mouse subcutaneous tumor model to detect the effect of FuHsi in mice. The experimental results show that FuHsi KD can significantly inhibit the growth of NCI-H1299 cells under the skin of nude mice, thereby causing them to form smaller tumors. In addition, the results of RNA agarose gel electrophoresis experiments showed that compared with the control group, the expression of 18S and 28S rRNA in the tumors from the FuHsi KD group was significantly reduced. These results show that FuHsi can promote the proliferation of tumor cells in vivo.
[0051] Taken together, these data suggest that high levels of FuHsi expression play an important promoting function in tumor progression.
[0052] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.
[0053] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.
Claims
1. An application of FuHsi microprotein, characterized in that: Includes any of the following applications: Application of FuHsi microprotein or its promoter in increasing protein or antibody production of cells; Application of FuHsi microprotein detection reagent in the preparation of a kit for tumor detection or poor prognosis assessment; and, the use of inhibitors of FuHsi microproteins in the preparation of anti-tumor drugs; Among them, the amino acid sequence of the FuHsi microprotein is: SEQ ID NO.
1.
2. The use according to claim 1, characterized in that: The FuHsi microprotein detection reagent includes Anti-FuHsi antibody, and the amino acid sequence is SEQ ID NO.
5.
3. The use according to claim 1, characterized in that: The inhibitors are shRNAs that can knock down the lncRNA corresponding to FuHsi, including: sh-1, sequence: SEQ ID NO.3; sh-2, sequence: SEQ ID NO.
4.
4. The use according to claim 1, characterized in that: The tumor is lung adenocarcinoma.
5. The use according to claim 1, characterized in that: The promoter includes lncRNA DLGAP1-AS2, the sequence of which is SEQ ID NO.2, and the coding sequence of FuHsi microprotein, the sequence of which is SEQ ID NO.
6.
6. An anti-tumor drug, characterized in that: The invention comprises an inhibitor of FuHsi microprotein, wherein the amino acid sequence of the FuHsi microprotein is: SEQ ID NO.
1.
7. The drug according to claim 6, characterized in that The inhibitors are shRNAs that can knock down the lncRNA corresponding to FuHsi, including: sh-1, sequence: SEQ ID NO.3; sh-2, sequence: SEQ ID NO.
4.
8. The drug according to claim 6, characterized in that Also included are vehicles for delivering the inhibitors.
9. A kit, characterized in that: It includes a reagent for detecting the content or expression amount of FuHsi microprotein, and the amino acid sequence of the FuHsi microprotein is: SEQ ID NO.
1.
10. The kit according to claim 9, characterized in that: The detection reagent of the FuHsi microprotein includes Anti-FuHsi antibody.
